Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Establishment Labs (NASDAQ:ESTA) had its price target raised by stock analysts at Canaccord Genuity Group from $60.00 to $72.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 10.95% from the stock’s previous close.

Several other brokerages have also recently issued reports on ESTA. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Mizuho lifted their price target on Establishment Labs from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Needham & Company LLC boosted their target price on shares of Establishment Labs from $48.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $66.00.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA traded up $4.39 during trading on Thursday, hitting $64.90. The stock had a trading volume of 1,071,251 shares, compared to its average volume of 490,987. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. Establishment Labs has a 12-month low of $26.56 and a 12-month high of $65.10. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -21.24 and a beta of 0.98. The stock has a 50-day simple moving average of $43.18 and a two-hundred day simple moving average of $39.99.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The company had revenue of $53.78 million for the quarter, compared to the consensus estimate of $52.28 million. During the same quarter in the prior year, the company earned ($0.59) EPS. Establishment Labs’s quarterly revenue was up 33.8% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Several large investors have recently made changes to their positions in the company. Mudita Advisors LLP boosted its position in shares of Establishment Labs by 15.6% during the first quarter. Mudita Advisors LLP now owns 479,359 shares of the company’s stock worth $19,560,000 after buying an additional 64,859 shares during the period. New York State Common Retirement Fund acquired a new position in Establishment Labs during the 1st quarter worth about $894,000. Milestone Asset Management LLC purchased a new position in Establishment Labs during the 2nd quarter valued at about $523,000. Swiss National Bank grew its position in Establishment Labs by 1.3% in the 1st quarter. Swiss National Bank now owns 39,000 shares of the company’s stock valued at $1,591,000 after acquiring an additional 500 shares in the last quarter. Finally, Pier Capital LLC purchased a new stake in Establishment Labs during the second quarter worth about $10,777,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.